Synthetic lethality: targeting damaged pathways
- Introduction - Synthetic lethality: targeting damaged pathways
- Exploiting synthetic lethality in DNA repair for cancer therapy
- Secondary mutation of BRCA1/2 as a mechanism of drug resistance in BRCA1/2-mutated cancer
- Exploiting hypoxia for anti-cancer therapy using a synthetic context lethality approach
- Complementary RNA interference and compound screens to identify novel therapeutic targets for mismatch repair deficient cancers
- DNA polymerases as potential therapeutic targets for DNA mismatch repair deficient cancers
- Development of human apurinic/apyrimidinic endonuclease (APE1) inhibitors for cancer therapy
